OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit www.conferenceseries.com

Back

Biography

Liu received his PhD in Physiological Sciences from the University of California, Los Angeles in 1990. He completed post-doctoral scientifi c training at Stanford University and then went on to a faculty position at Massachusetts Institute of Technology. Liu continued a vigorous scientifi c research program at Tsinghua University, and leads and oversee as CEO the multiple clinical development programs of Neurocentria. He is a world renowned expert in synaptic physiology, learning, andmemory. His research focuses primarily on discovering principles that regulate synapse density in the brain under physiological and pathological conditions and developing novel strategies for treating neurodegeneration and preventing brain atrophy.

Abstract

Background: Age-related cognitive decline is a major problem in elderly, aff ecting quality of life. Pre-clinical studies show that MMFS-01, a synapse density enhancer, is eff ective at reversing cognitive decline in aging rodents. Objective: Since brain atrophy during aging is strongly associated with both cognitive decline and sleep disorder, we evaluated the effi cacy of MMFS-01 in its ability to reverse cognitive decline and improve sleep. Methods: We conducted a randomized, double-blind, placebo-controlled, parallel designed trial in elderly subjects (age 50- 70) with complaints of memory impairment, sleep disorder, and anxiety. Subjects were treated with MMFS-01 (n=23) or placebo (n=21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains. Results: With MMFS-01 treatment, overall cognitive ability improved signifi cantly relative to placebo (p=0.002; Cohen’s d=0.92). Age-related cognitive fl uctuation was also reduced. Although the study population had more severe executive function defi cits than age-matched controls, MMFS-01 treatment nearly restored impaired executive function, demonstrating that MMFS-01 was clinically signifi cant. Sleep quality and anxiety were improved in MMFS-01 treatment group; however, similar degrees of improvement were also observed in the placebo control group. Conclusions: Th e current study demonstrates the potential of MMFS-01 for treating age-related cognitive decline in elderly.